Kornimate/medical-research-clean huggingface dataset:
chronic wound care of lower limb in m@dicicat center at chu de martinique

Conditions: Chronic Wounds

Summary: chronic wound of lower limb. in developed countries, the prevalence of chronic wounds is linked to the ageing of the population and the increase in chronic diseases such as diabetes, obesity and cardiovascular disease. consequence: amputations of lower limb. the prevalence of chronic wounds is also variable across the globe. in addition, chronic wounds are associated with psychosocial problems such as poor quality of life, loss of professional activity and progressive de-socialization of patients. to improve the quality of care we need in french wound assessment tools validated scientifically like the resvech 2.0 scale, validated in the spanish language.

the valrescic study aims to perform a cross-cultural and psychometric validation of the resvech 2.0 scale in order to be able to use it for monitoring wounds in both hospital and primary care settings in the french west indies. the resvech 2.0 scale is a heterogeneous scale to monitor the evolution of a chronic wound. this scale was created in 2010 and consists of 6 items with response modalities ranging from 5 to 14. the interpretation of the scale parameters may differ depending on the cultural context. the resvech 2.0 scale has been validated in the spanish language (in spain and colombia) to assess the progress towards healing of pressure ulcers and chronic wounds of the lower limbs. for the cross-cultural evaluation we will follow beaton's methodology, which includes: translation, synthesis, retro-translation, expert committee review and pre-testing. for the psychometric validation, the following parameters will be measured: feasibility and acceptability, validity, reliability, and sensitivity to change.

Eligibility criteria:
inclusion criteria: * patients with at least one chronic wound of the lower limbs admitted to the m@dicicat® healing centre. * patients agreeing to participate in the study * patients affiliated to a social security scheme exclusion criteria: * patients with critical ischemia of the lower limb concerned * patients under legal protection measures (guardianship, curatorship, safeguard of justice) and persons deprived of liberty

Keywords: chronic wounds resvech 2.0 wound assesment tool cross-cultural validation,
safety study to explore combination of gefitinib (zd1839, iressa) and radiotherapy in non-metastatic prostate cancer

Conditions: Non-Metastatic Prostate Cancer

Summary: to estimate the safety and tolerability of 250 mg zd1839 given concurrently with 3d-crt in patients with non-metastatic prostate cancer


Eligibility criteria:
inclusion criteria: * biopsy confirmation of localised (t2) or locally advanced (t3) prostate cancer * psa below 20 ng/ml * lymph node negative * non-metastatic * written informed consent exclusion criteria: * well differentiated stage t2 prostate cancer (gleason score 2 to 4) * distant or nodal metastases * prostatectomy * concomitant lhrh analog treatment * previous or concomitant anti-androgens * active ild
symptoms and wellbeing of people infected with covid-19 virus in iceland

Conditions: Covid19

Summary: the purpose of this cross-sectional study is to explore symptoms and well being of people diagnosed with covid-19 from the outset of the pandemic until june 2020.

all patients diagnosed with covid-19 in iceland were referred to the covid-19 outpatient clinic at landspitali national university hospital in iceland. in the clinic risk assessment was conducted and the patients were accordingly provided with individualized care be it telephone surveillance, onsite examination and treatment, or admission to the hospital. as the the first wave of the pandemic was curbing the necessity of exploring how the patients did and continue to fare after being infected became apparent. the research questions are: what were the symptoms that patients expressed during and about three months after being diagnosed with covid-19? what is the prevalence and intensity of the symptoms that patients expressed during and about three months after being diagnosed with covid-19 ? how do patients value their health related quality of life, what is their health literacy and sense of security in care during and about three months after being diagnosed with covid-19 ? how do patients value the nursing care in the outpatient covid-19 clinic? what are the patients' perception of having caught covid-19?

Eligibility criteria:
inclusion criteria: * patients receiving care from the covid-19 outpatient clinic at luh during the first wave of the pandemic exclusion criteria: * young than 18 y.o. * do not understand icelandic * died

Keywords: covid19 symptoms well being survey
glimepiride vs metformin as monotherapy in pediatric subjects with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: to compare the change in glycemic control from baseline to endpoint (last available posttreatment assessment) as measured by hba1c in pediatric subjects with type 2 diabetes receiving either glimepiride or metformin as monotherapy.


Eligibility criteria:
inclusion criteria: 1. subjects who had type 2 diabetes treated with diet and exercise only for at least 2 weeks prior to randomization, or who were previously or currently treated with an oral agent and had not responded to diet, exercise, and oral therapy for at least 3 months (documented by an hba1c \>7.5%). 2. subjects who completed glimepiride pharmacokinetic study hoe 490/4045 at preselected sites within 3 weeks prior to the screening period were also permitted to enroll. 3. subjects were required to be negative for islet cell antigen (ica) and glutamic acid decarboxylase (gad) autoantibodies and to have a c-peptide level at 90 minutes of ≥ 1.5 ng/ml. the hba1c was required to be \>7.1% at screening and \<12.0% on the day of randomization. exclusion criteria: subjects meeting any of the following criteria were not to be included in the study: 1. a history of an acute metabolic complication such as diabetic ketoacidosis within 3 months before screening 2. on insulin therapy, or had received insulin for \>6 weeks, 3 months prior to randomization 3. on weight-reduction medication 4. known hypersensitivity to biguanides, sulfonamides, or insulin 5. pregnant or lactating females 6. clinically significant renal (serum creatinine level \>1.0 mg/dl) or hepatic disease (alanine aminotransferase \[alt\] or aspartate aminotransferase \[ast\] \>2.5 times the upper limits of normal \[uln\]) 7. gi disorders that may interfere with the absorption of the study drugs 8. chronic use of medications known to affect glucose levels such as intermittent use of systemic corticosteroids or large dose of inhaled steroids 9. clinically significant laboratory abnormality on screening laboratory tests or any medical condition that in the opinion of the investigator would affect the outcome of the study 10. history of drug or alcohol abuse 11. treatment with any investigational product in the last 3 months before study entry 12. history of noncompliance with regard to follow-up medical care 13. any disease or condition that in the opinion of the investigator and/or sponsor may interfere with completion of the study
efficacy of sterol enhanced soy beverage on cholesterol metabolism, inflammation and oxidative status in humans

Conditions: Coronary Heart Disease

Summary: it is becoming increasingly clear that north americans prefer dietary approaches to enhance health in favour of pharmaceutical approaches. although the consumption of various phytosterol (ps)-enriched foods have been shown to be effective in lowering plasma cholesterol in a variety of food matrices, the lipid-lowering potential of ps-enriched soymilk has not been investigated. therefore, the objective of this investigation was to examine the lipid-lowering efficacy of a ps-enriched soymilk beverage in comparison to a 1% dairy milk control. twenty-three hypercholesterolemic subjects (total-cholesterol and ldl-cholesterol ≥ 5.0 and 3.5 mmol/l, respectively) consumed 3 tetrapacs per day of a phytosterol-enriched soy beverage providing 1.95g ps/d or a 1% dairy milk control. the study was conducted as a 28 d controlled dietary intervention according to a completely randomized, two-period cross-over design.


Eligibility criteria:
inclusion criteria: 1. healthy males and females, aged 19-60 yr, will be screened for determination of fasting circulating ldl-cholesterol and tg levels. 2. subjects accepted into the study will have plasma ldl-c 130-200 mg/dl, tg levels below 250 mg/dl. 3. the inclusion for body mass index (bmi) range will be 22 to 32 kg/m2. 4. subjects must also demonstrate an ability to understand dietary procedures and exercise procedures and be judged as compliant and motivated by the investigators. 5. subjects will be permitted to take stable doses of thyroid hormone and anti-hypertensive agents, as long as these are continued equivalently throughout the duration of study. exclusion criteria: 1. history of recent (i.e. less than 3 months) or chronic use of oral hypolipidemic therapy, including fish oils, or probucol within the last 6 months. 2. history of chronic use of alcohol (\> 2 drinks/day), systemic antibodies, corticosteroids, androgens, or phenytoin. 3. myocardial infarction, coronary artery bypass, or other major surgical procedures within the last six months. 4. recent onset of angina, congestive heart failure, inflammatory bowel disease, pancreatitis, diabetes, or significant current (ie. onset within past three months) gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of active lesions, chemotherapy or surgery in the past year). 5. exercise greater than 15 miles/wk or 4,000 kcal/wk.

Keywords: cholesterol plant sterols cholesterol absorption
women-focused hiv prevention in the western cape

Conditions: HIV; Substance Abuse; Violence

Summary: the purpose of this study is to test the effectiveness of a woman-focused hiv prevention intervention combined with voluntary counseling and testing (vct), compared to vct only, and vct combined with an attention-control nutrition intervention.

surveillance data indicate that hiv risk and substance use is a serious problem among south african women. this study, funded by the national institute on child health and human development (nichd), builds on findings from a recently completed pilot study among women in less affluent townships and communities in the western cape (wechsberg et al., 2008). the pilot study tested the effectiveness of an evidence-based woman-focused intervention in reducing drug use, sexual risk, and victimization by addressing the intersection of these factors among 100 poor, substance-using women of colour. the primary aim of this study is to test the effectiveness, through a randomized controlled trial (rct), of vct plus a woman-focused intervention relative to vct only to increase knowledge and skills to reduce substance abuse, sexual risk, and victimization, and to an equal-attention (nutrition) control group at 3-, 6-, 9-, and 12-month follow-ups. a secondary aim is to examine the moderating effect of victimization (i.e., sexual and physical) and the mediating effects of hiv risk knowledge, condom use skills, sexual negotiation assertiveness, and relationship power on the effectiveness of the woman-focused groups to decrease risk related to drug use, sexual risk, and sex-related-victimization relative to the rapid testing group and to the equal-attention control group.

Eligibility criteria:
inclusion criteria: * to be eligible for the study, participants must be: (a) female; (b) report use of at least two drugs-alcohol, marijuana, methamphetamine (tik), mandrax (methaqualone), cocaine (crack and/or powder), heroin (thai white), glue, mdma (ecstasy), or lsd-at least once a week in the past 90 days; (c) be sexually active within the past 30 days with a male partner; (d) be aged 18 to 33 years; (e) live in the communities around the airport; and (f) provide verbal consent to be screened for eligibility and written consent to participate in the study. exclusion criteria: * if participants do not meet all of the inclusion criteria, they will be excluded from the study.

Keywords: hiv sexual risk substance abuse victimization violence voluntary counseling and testing (vct)
representation of diet in the management of type 2 diabetes in migrant patients at chsd

Conditions: Diabetes Mellitus, Type 2

Summary: this observational and monocentric study aims to explore how migrant patients with type 2 diabetes perceive and represent food in the context of their diabetes care. conducted at the centre hospitalier de saint-denis, the study investigates the cultural, social, and personal factors that influence dietary habits and how these perceptions affect the management of their condition. the goal is to improve the understanding of patient behaviors and support more culturally adapted care strategies.


Eligibility criteria:
inclusion criteria: * type 2 diabetic for at least 3 months * arrived in france less than 7 years ago * adult patient (age 18) * speaking french or english exclusion criteria: * minor patient (age \< 18 years) * type 1 diabetes * does not speak french or english * patient who has expressed opposition to the use of his data, or his refusal to participate
atomoxetine treatment for cognitive impairment in parkinson's disease (atm-cog)

Conditions: Parkinson's Disease; Cognitive Impairment

Summary: the purpose of this study is to determine the safety and effectiveness of a drug called atomoxetine for the treatment of cognitive impairment for parkinson 's disease. atomoxetine (atm) is an approved drug currently on the market for the treatment of attention deficit. it works to increase the amount of norepinephrine (a chemical in the brain that helps keep us awake and alert) in our brain. atm has not been approved by the food and drug administration (fda) to be used in the treatment of pd.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of idiopathic pd according to the united kingdom parkinson's disease society brain bank (ukpdsbb) criteria * male or female subjects aged between 35 and 75 years, inclusive at the time of consent * hoehn \& yahr stage i-iv * diagnosis of pd mild cognitive impairment (mci), montreal cognitive assessment (moca) score 21-25 * stable concomitant medications for 60 days exclusion criteria: * secondary parkinsonism or atypical parkinsonism, prior deep brain stimulation (dbs) or other brain surgery * pd dementia; moca score \<21 * presence of psychosis, pregnancy, suicidal ideation on the columbia suicide severity rating scale (c-ssrs) type 4 or 5 in past 3 months. * current treatment with anticholinergics, monoamine oxidase (mao) inhibitors or neuroleptics (including quetiapine) * serious cardiac abnormalities, narrow angle glaucoma, pheochromocytoma, bipolar disorder * liver function tests (lfts) \>1.5 x upper limit of normal value

Keywords: parkinson's disease
ultrasonographic evaluation of respiratory muscles in stroke patients

Conditions: Respiratory Muscle; Pulmonary Function Test

Summary: ultrasonographic evaluation of respiratory muscle thickness in stroke patients, determination of its correlation with pulmonary function test (pft) , and the first evaluation method to determine respiratory rehabilitation goals and to use it in the follow-up of the effectiveness of the treatment.

the study is planned as a cross-sectional prospective study. healthy volunteers and stroke patients who are planned to be hospitalized in the stroke clinic for rehabilitation in istanbul physical medicine rehabilitation training and research hospital are evaluated and included in the study according to the inclusion and exclusion criteria. demographic data of patients (gender, age, height, weight, body mass index, comorbidity status, smoking/alcohol use, dominant extremity, stroke etiology, duration, side), functional status (brunnstrom stages, functional ambulation scale (fas), daily living activity (adl) index), pulmonary function test (pft) measurement results and bilateral diaphragm and abdominal muscle thicknesses and thickening ratio in ultrasonography, demographic data of healthy volunteers (gender, age, height, weight, body mass index, comorbidity status, smoking/alcohol use, dominant side), pft measurement results and the dominant side diaphragm and abdominal muscle thicknesses and thickening ratio in ultrasonography is done and included in the study. in the ultrasonographic evaluation of the participants, using a 7-12 mhz linear probe, measurements are made of the diaphragm at the end of tidal expiration and forced inspiration, abdominal muscles at the end of tidal expiration and at the end of forced expiration, while all respiratory muscles are lying in the supine position. diaphragm thickness is measured between the 8th and 9th ribs at the level of the anteroaxillary line, rectus abdominis; 4 cm lateral of the umbilicus, transversus abdominis, external oblique, internal oblique muscles' measurement is made from the middle of the lowest part of the 12. rib and the highest point of the iliac crest and 2.5 cm in front of the midaxillary line. all measurements are repeated 3 times and the average value will be recorded. vital capacity\[vc\], forced vital capacity \[fvc\], forced expiratory volume 1 second \[fev1\] , fev1/fvc, maximal expiratory flow rate \[pef\], maximum inspiratory pressure \[mip\] maximum expiratory pressure \[mep\] in patients' pft \] measurement results are checked. intragroup and intergroup data are compared.

Eligibility criteria:
inclusion criteria: * ischemic or hemorrhagic stroke patients * stroke duration \>6 months * mini-mental test score \>24 exclusion criteria: * individuals with acute or chronic lung disease * patients with a history of thoracic or abdominal surgery * patients with other neuromuscular diseases * aphasia type with impaired understanding * facial paralysis

Keywords: stroke pulmonary function ultrasound respiratory muscle thickness
influence of cyp2c9 genotype on clinical efficacy of tenoxicam

Conditions: Molar, Third; Pain

Summary: the goal of this study is to evaluate the different gene haplotypes for the clinical efficacy of tenoxicam after third lower molar surgery for pain, edema and trismus, adverse reactions, need of rescue medication, patient satisfaction regarding the drug and the pharmacokinetics of the drug between the different gene haplotypes for cyp2c9 that are found in this population

pharmacogenetics is an area of pharmacology that studies the contribution of genetic factors to individual responses to drugs. this branch of science involves the variability in pharmacodynamics and pharmacokinetics through the study of polymorphisms in genes encoding receptors, as well as in drug metabolism, where this area of pharmacology has been growing and achieving its first results with clinical use. the nsaids are metabolized by cytochrome p450 (cyp) family, predominantly cyp2c9. the goal of this study is to evaluate the different gene haplotypes for the clinical efficacy of tenoxicam after third lower molar surgery for pain, edema and trismus, adverse reactions, need of rescue medication, patient satisfaction regarding the drug and the pharmacokinetics of the drug between the different gene haplotypes for cyp2c9 that are found in this population. therefore, 100 patients will be genotyped and phenotyped for this gene and their postoperative data will be confronted with the data found in the brazilian population. for the analysis of the proposed gene, saliva will be collected and serve as a source of genomic dna. for the molecular analysis, polymerase chain reaction (pcr) with tests validated and produced by applied biosystems® will be performed. the analysis of the results will be described with a significance level of 0.05.

Eligibility criteria:
inclusion criteria: * impacted lower third molar; * not making use of nonsteroidal anti-inflammatory drugs in the last 7 days; exclusion criteria: * local anesthetics allergy; * history of gastrointestinal bleeding or ulcers; * kidney disease; * asthma; * allergy or sensitivity to aspirin or any other anti-inflammatory non-steroid agent; * pregnant or nursing women; * patients using antidepressant, diuretic or aspirin; * patients received antibiotics for 30 days prior to surgery.
ps150 total knee arthroplasty outcomes registry

Conditions: Osteoarthritis; Rheumatoid Arthritis

Summary: this registry is intended to evaluate the clinical outcomes of the depuy p.f.c. sigma ps150 rp total knee system. 200 participants will be enrolled prospectively or retrospectively and the follow up period will be 5 years. data collection will include radiographic analysis, knee society evaluation and adverse events.


Eligibility criteria:
inclusion criteria: * primary total knee replacement for any indication in accordance with the instructions for use accompanying the sigma ps150 implant. * signed informed patient consent exclusion criteria: * there are no exclusion criteria for this registry.
understanding variability in behavioral weight loss treatment response in young women (ready set health)

Conditions: Weight Loss; Weight Change, Body; Overweight or Obesity

Summary: this study is a single-arm behavioral weight loss intervention for emerging adult women with in-person assessments at 0 (baseline) and 4 months (post-treatment) in addition to ema data collection regarding risk factors known to interfere with program engagement and weight loss in this high-risk population (e.g., sleep, psychological distress, life events).

this study will implement a 4-month internet-based behavioral weight loss intervention in order to collect ecological momentary assessment (ema) data that will shed light on real-time barriers to weight management. the intervention is evidence-based and adapted with respect to content and delivery mode in order to meet the needs of emerging adult women. consenting and eligible participants will receive 1 virtual group session led by a trained interventionist followed by weekly emails directing them to an intervention website housing video and .pdf content, weekly text messages, emailed tailored feedback regarding their weight loss behaviors and progress, and a closed facebook group to facilitate social support. all participants will be followed for 4 months with hybrid in-person/virtual assessments at 0 and 4 months; in addition, all participants will be asked to respond to ema prompts throughout the 4-month intervention period (week 2, week 4, week 7, and week 13).

Eligibility criteria:
inclusion criteria: * 18-25 years of age * bmi (body mass index) 25-45 kg/m2 * female gender identity exclusion criteria: * report of uncontrolled medical condition that may pose a safety issue given the recommendations for the diet and unsupervised physical activity * diagnosed cardiovascular or metabolic disease * report of a heart condition, chest pain during periods of activity or rest, or loss of consciousness * recent change in use of medications that may impact weight or metabolic function * cancer in the past 5 years, except non-melanoma skin cancers or early-stage cervical cancer * current symptoms of alcohol or other substance dependence * report of diagnosis or history of anorexia nervosa or bulimia nervosa, or any compensatory behaviors within the previous 3 months * hospitalization for depression or other psychiatric disorder within the past 12 months * lifetime history of bipolar disorder or psychotic disorder * planning to move from the area within the study period * currently pregnant, pregnant within the past 6 months, currently breastfeeding or planning to become pregnant within the next 6 months * current involvement in a weight loss program or current use of weight loss medication * recent significant weight loss * inability to read or speak english * lack of a smartphone or unwillingness to use it for study components

Keywords: emerging adults women weight loss barriers